Patent · US Active

Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor

US11027013B2 · kind B2 · utility

0Cited by

8References

6Claims

0Family size

Assignees

Deutsches Krebsforschungszentrum · DE
RUPRECHT - KARLS - UNIVERSITÄT HEIDELBERG · DE

Inventors

Barbara Leuchs · Heidelberg, DE
Antonio Marchini · Heidelberg, DE
Jean Rommelaere · Heidelberg, DE
Assia Angelova · Heidelberg, DE
Dirk Jager · New York, US
Wolfgang Wick · Heidelberg, DE
Michael Dahm · Munich, DE

Key dates

Filing date	Oct 1, 2018
Grant date	Jun 8, 2021
Priority date	—
Expiry date	Dec 8, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2750/14332
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.